Columbia Engineering and Dana-Farber Cancer Institute researchers discovered that a specific T cell population plays a key role in successful immunotherapy for relapsed acute myeloid leukemia (AML). Using machine learning (DIISCO), they found that the patient's immune environment, not donor cells, determines success. This breakthrough could lead to personalized treatments and improved survival rates for AML patients.
(Image Source: Columbia Engineering)
Immune Cells That Boost Leukemia Survival: In a remarkable step forward for cancer immunotherapy, a research team from Columbia Engineering and the Irving Institute for Cancer Dynamics, in collaboration with the Dana-Farber Cancer Institute (DFCI), has uncovered a crucial factor that may determine the success of treatment for relapsed acute myeloid leukemia (AML). Their findings, published today in Science Immunology, reveal that a specific population of T cells—previously overlooked—may hold the key to better survival rates for patients undergoing donor lymphocyte infusion (DLI).
Their research not only sheds light on why some AML patients respond to immunotherapy. In contrast, others do not, but it also paves the way for new, personalized treatment approaches that could significantly improve outcomes for relapsed AML patients. This group currently faces a bleak prognosis.
AML is an aggressive cancer that originates in the bone marrow before quickly spreading into the bloodstream. According to the National Cancer Institute, the disease affects approximately four out of every 100,000 people in the U.S. each year. Standard treatment typically involves chemotherapy followed by a stem cell transplant, but even with this approach, relapse rates remain high. Up to 40% of patients relapse after transplant, and for these individuals, survival is grim—most live only six months after relapse.
At this stage, immunotherapy—which uses the body's immune system to fight cancer—becomes the last resort. The primary treatment, donor lymphocyte infusion (DLI), involves transferring immune cells from a healthy donor into the patient's body to kill the leukaemia cells. However, DLI has a success rate of only 24% over five years. The question scientists have been grappling with is: Why do some patients benefit from DLI while others do not?
Led by Elham Azizi, an associate professor of biomedical engineering at Columbia Engineering, the research team took a deep dive into the bone marrow immune environment of AML patients receiving DLI. They wanted to understand the role of immune cell interactions in determining whether a patient would respond to the treatment.
Using a combination of computational modelling and experimental analysis, the team made a groundbreaking discovery: a specific population of T cells, present in patients who responded well to treatment, might be the missing link to understanding successful immunotherapy outcomes.
These unique T cells help boost the body's immune response against leukemia, making them a crucial element in effective treatment. But that wasn't all—the research also found that patients with a healthier, more diverse immune environment in their bone marrow could better support these T cells, allowing them to fight the disease more effectively.
One of the most innovative aspects of this study was the use of DIISCO, a proprietary machine-learning method developed by the research team. DIISCO was used to analyze complex immune cell interactions over time, focusing on how these interactions changed in both responders (patients whose cancer went into remission) and non-responders (patients who did not benefit from DLI).
The most surprising finding? The success of the treatment had little to do with the donor's immune cell composition—a factor previously believed to be critical. Instead, the patient's immune environment played the defining role in determining whether the treatment worked.
This finding suggests that simply infusing healthy donor immune cells into a patient isn't enough—what truly matters is how well the patient's immune system supports these new cells.
This discovery opens the door for new intervention strategies that could dramatically improve survival rates for relapsed AML patients.
One of the most promising ideas is to optimize a patient's immune environment before beginning DLI treatment. This could involve:
Doctors can significantly improve treatment success rates by ensuring that the patient’s immune system is in the best possible condition before receiving DLI.
The findings were further confirmed through functional experiments, providing strong evidence that these T cells play a direct role in successful immunotherapy.
"Seeing our findings validated through functional experiments is incredibly exciting and offers real hope for improving cancer immunotherapy," said Cameron Park, a PhD student in the Azizi lab and co-lead author of the study.
Park and Katie Maurer from the Catherine Wu Lab at Dana-Farber Cancer Institute were instrumental in conducting the research. The DIISCO algorithm, which helped uncover these crucial insights, was co-developed by Park, adding another layer of significance to the study.
While this discovery represents a significant advancement, there's still a lot of work to be done before these findings can be translated into clinical treatments.
Professor Azizi emphasizes the importance of this multidisciplinary approach:
"This research exemplifies the power of combining computational and experimental methods through close collaboration to answer complex biological questions and uncover unexpected insights," she said. “Our findings not only shed light on mechanisms underlying successful immunotherapy response in leukemia but also provide a roadmap for developing effective treatments guided by innovative machine learning tools.”
This study has the potential to revolutionize cancer immunotherapy. By shifting the focus from donor immune cells to the patient's immune environment, researchers may be able to develop more effective and personalized treatment strategies. For relapsed AML patients, this could mean the difference between hope and hopelessness.
With continued research and clinical trials on the horizon, the insights gained from this study could lead to lifesaving advancements in the fight against one of the deadliest forms of leukemia. And for the millions affected by cancer worldwide, this is a discovery worth celebrating. Stay tuned at Education Post News for more global updates.
Loading ...
Copyright© educationpost.in 2024 All Rights Reserved.
Designed and Developed by @Pyndertech